Trends and determinants of antimicrobial susceptibility of Neisseria gonorrhoeae in the Netherlands, 2007 to 2015
- PMID: 30205870
- PMCID: PMC6134804
- DOI: 10.2807/1560-7917.ES.2018.23.36.1700565
Trends and determinants of antimicrobial susceptibility of Neisseria gonorrhoeae in the Netherlands, 2007 to 2015
Abstract
BackgroundNeisseria gonorrhoeae antibiotic resistance surveillance is important to maintain adequate treatment. We analysed 2007-15 data from the Gonococcal Resistance to Antimicrobials Surveillance (GRAS), which currently includes 19 of 25 sexually transmitted infection (STI) centres in the Netherlands. Methods: From each patient with a gonorrhoea culture, the minimum inhibitory concentration (MIC) for several antibiotics was determined. Time trends were assessed by geometric means and linear regression of logarithmic MIC. Determinants for decreased susceptibility to ceftriaxone (MIC > 0.032 mg/L) and resistance to cefotaxime (MIC > 0.125 mg/L) and azithromycin (MIC > 0.5 mg/L) were assessed using stratified logistic regression. Results: 11,768 isolates were analysed. No ceftriaxone resistance was found. In 2015, 27 of 1,425 isolates (1.9%) were resistant to cefotaxime and 176 of 1,623 (10.9%) to azithromycin. Ceftriaxone susceptibility showed no trend (p = 0.96) during the study period, but cefotaxime MIC decreased (p < 0.0001) and azithromycin MIC increased (p < 0.0001) significantly. Concerning ceftriaxone, isolates of men who have sex with men (MSM) from 2013 (p = 0.0005) and 2014 (p = 0.0004) were significantly associated with decreased susceptibility. Significant determinants for cefotaxime resistance were having ≥ 6 partners for women (p = 0.0006). For azithromycin,isolates from MSM collected in 2012 (p = 0.0035), 2013 (p = 0.012), and 2014 (p = 0.013), or from non-Dutch (p < 0.0001) or older (≥ 35 years; p = 0.01) MSM were significantly associated with susceptibility. Resistance in heterosexual men was significantly associated with being ≥ 25 years-old (p = 0.0049) or having 3-5 partners (p = 0.01). Conclusions: No ceftriaxone resistance was found, but azithromycin MIC increased in 2007-15. Resistance determinants could help with focused intervention strategies.
Keywords: antimicrobial resistance; gonorrhoea; sexually transmitted infections.
Conflict of interest statement
Figures


Similar articles
-
Trends in antimicrobial susceptibility for azithromycin and ceftriaxone in Neisseria gonorrhoeae isolates in Amsterdam, the Netherlands, between 2012 and 2015.Euro Surveill. 2017 Jan 5;22(1):30431. doi: 10.2807/1560-7917.ES.2017.22.1.30431. Euro Surveill. 2017. PMID: 28079519 Free PMC article.
-
Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance - The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014.MMWR Surveill Summ. 2016 Jul 15;65(7):1-19. doi: 10.15585/mmwr.ss6507a1. MMWR Surveill Summ. 2016. PMID: 27414503
-
Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in Neisseria gonorrhoeae in 24 European Countries, 2015.BMC Infect Dis. 2017 Sep 11;17(1):617. doi: 10.1186/s12879-017-2707-z. BMC Infect Dis. 2017. PMID: 28893203 Free PMC article.
-
Systematic review and survey of Neisseria gonorrhoeae ceftriaxone and azithromycin susceptibility data in the Asia Pacific, 2011 to 2016.PLoS One. 2019 Apr 3;14(4):e0213312. doi: 10.1371/journal.pone.0213312. eCollection 2019. PLoS One. 2019. PMID: 30943199 Free PMC article.
-
Antimicrobial-resistant gonorrhoea: the national public health response, England, 2013 to 2020.Euro Surveill. 2022 Oct;27(40):2200057. doi: 10.2807/1560-7917.ES.2022.27.40.2200057. Euro Surveill. 2022. PMID: 36205171 Free PMC article. Review.
Cited by
-
Trends and regional variations of gonococcal antimicrobial resistance in the Netherlands, 2013 to 2019.Euro Surveill. 2022 Aug;27(34):2200081. doi: 10.2807/1560-7917.ES.2022.27.34.2200081. Euro Surveill. 2022. PMID: 36017715 Free PMC article.
-
Effect on the Resistome of Dual vs Monotherapy for the Treatment of Neisseria gonorrhoeae: Results From a Randomized Controlled Trial (ResistAZM Trial).Open Forum Infect Dis. 2023 Sep 8;10(10):ofad462. doi: 10.1093/ofid/ofad462. eCollection 2023 Oct. Open Forum Infect Dis. 2023. PMID: 37854109 Free PMC article.
-
Antimicrobial susceptibility of Neisseria gonorrhoeae in Barcelona during a five-year period, 2013 to 2017.Euro Surveill. 2020 Oct;25(42):1900576. doi: 10.2807/1560-7917.ES.2020.25.42.1900576. Euro Surveill. 2020. PMID: 33094716 Free PMC article.
-
Association between city-level sociodemographic and health factors and the prevalence of antimicrobial-resistant gonorrhea in the US, 2000-2019: a spatial-temporal modeling study.Lancet Reg Health Am. 2025 Jan 31;43:101006. doi: 10.1016/j.lana.2025.101006. eCollection 2025 Mar. Lancet Reg Health Am. 2025. PMID: 39968293 Free PMC article.
-
Global status of Azithromycin and Erythromycin Resistance Rates in Neisseria gonorrhoeae: A Systematic Review and Meta-analysis.Yale J Biol Med. 2022 Dec 22;95(4):465-478. eCollection 2022 Dec. Yale J Biol Med. 2022. PMID: 36568835 Free PMC article.
References
-
- World Health Organization (WHO). Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva: WHO; 2012.
-
- Van den Broek IVF, van Aar F, van Oeffelen AAM, Op de Coul ELM, Woestenberg PJ, Heijne JCM, et al. Sexually transmitted infections in the Netherlands in 2015. Bilthoven: National Institute for Public Health and the Environment (RIVM); 2016. Available from: https://www.rivm.nl/bibliotheek/rapporten/2016-0027.html
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical